An inactivated trivalent virion-based vaccine protects against aerosol challenge with encephalitic alphaviruses in mice and macaques
Science Translational Medicine · 2025
DOI: 10.1126/scitranslmed.adv7079 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, 2025. Verfasst von L K Metthew Lam und 20 weiteren Autor:innen. Beteiligte Einrichtung: Center for Vaccine Research and Department of Immunology, University of Pittsburgh, Pittsburgh, PA 15261, USA. Hauptthemen laut MEDLINE: Alphavirus, Vaccines, Inactivated, Viral Vaccines, Virion. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NIAID NIH HHS.
Abstract (Originalsprache)
Venezuelan (VEEV), Eastern (EEEV), and Western (WEEV) equine encephalitis viruses are mosquito-transmitted alphaviruses in the family Togaviridae with the potential to cause fatal neuroinvasive disease in humans. These viruses can also be infectious when aerosolized and, thus, are potential biothreat agents. Human infection can progress rapidly to encephalitis, with fatality rates of 1 to 10% in symptomatic VEEV and WEEV infections and 30 to 70% in symptomatic EEEV infections. Currently, there are no antiviral agents or vaccines approved for encephalitic alphaviruses. An investigational live-attenuated VEEV vaccine was generated more than 40 years ago but is highly reactogenic, poorly immunogenic, and causes disease in up to 20% of recipients. Formalin-inactivated vaccines for EEEV and WEEV are also poorly immunogenic and no longer available. Here, we developed a trivalent vaccine against VEEV, EEEV, and WEEV using a combination of attenuated chimeric Sindbis-VEEV/EEEV/WEEV viruses to streamline production and an H 2 O 2 inactivation treatment for enhanced safety and virion surface epitope preservation. The vaccines were adjuvanted with alum and tested for immunogenicity and protection in mouse and nonhuman primate models of lethal, aerosolized alphavirus infection. Two doses conferred complete protection in mice, and a similar regimen showed substantial or complete protection in nonhuman primates when administered at low and high doses, respectively. These results suggest that this inactivated vaccine is effective against the three encephalitogenic alphaviruses and may meet the need to counter the public health threat and biothreat posed by these viruses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Vaccine Research and Department of Immunology, University of Pittsburgh, Pittsburgh, PA 15261, USA.
- Virology Division, United States Army Military Institute for Infectious Diseases, Frederick, MD 21702, USA.
- Oregon Health & Science University, Beaverton, OR 97006, USA.
- National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA 02118, USA.
- Department of Pathology and Laboratory Medicine, Chobanian and Avedisian School of Medicine, Boston University, Boston, MA, 02118, USA.
- Department of Virology, Immunology, and Microbiology Chobanian and Avedisian School of Medicine, Boston University, Boston, MA, 02118, USA.
ORCID-Profile: L K Metthew Lam, Theron Gilliland, Matthew Dunn, Maria D Alcorn-Burckhardt, Shauna Vasilatos, Connor Williams, Amanda Laughlin, Christina L Gardner, Archana Thomas, Nicholas A Crossland, Douglas S Reed, Michael S Diamond, Mark K Slifka, William B Klimstra
Förderung
- NIH HHS
- NIAID NIH HHS
Zitieren
APA
Lam, L. K. M., Gilliland, T., Dunn, M., Alcorn-Burckhardt, M. D., Terada, Y., Sun, C., Vasilatos, S., Midgett, M., Williams, C., Laughlin, A., Lundy, J., Gardner, C. L., Thomas, A., Raué, H. P., Gertje, H. P., O'Connell, A. K., Crossland, N. A., Reed, D. S., Diamond, M. S., …, & Klimstra, W. B. (2025). An inactivated trivalent virion-based vaccine protects against aerosol challenge with encephalitic alphaviruses in mice and macaques. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.adv7079
Vancouver
Lam LKM, Gilliland T, Dunn M, Alcorn-Burckhardt MD, Terada Y, Sun C, et al. An inactivated trivalent virion-based vaccine protects against aerosol challenge with encephalitic alphaviruses in mice and macaques. Science Translational Medicine. 2025. doi:10.1126/scitranslmed.adv7079
BibTeX
@article{Lam2025,
author = {Lam, L K Metthew and Gilliland, Theron and Dunn, Matthew and Alcorn-Burckhardt, Maria D and Terada, Yutaka and Sun, Chengqun and Vasilatos, Shauna and Midgett, Morgan and Williams, Connor and Laughlin, Amanda and Lundy, Jeneveve and Gardner, Christina L and Thomas, Archana and Raué, Hans-Peter and Gertje, Hans P and O'Connell, Aoife K and Crossland, Nicholas A and Reed, Douglas S and Diamond, Michael S and Slifka, Mark K and Klimstra, William B},
title = {An inactivated trivalent virion-based vaccine protects against aerosol challenge with encephalitic alphaviruses in mice and macaques},
journal = {Science Translational Medicine},
year = {2025},
doi = {10.1126/scitranslmed.adv7079}
}
EUVIMED